Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | TPH1 | P17752 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765093 | 0.95 | CCR1 (0.42) | CCR1PPARGGAATPH1ALDH1A1 | |
| SCHEMBL15230430 | 0.91 | CCR1 (0.40) | CCR1PPARGKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL12636272 | 0.90 | CCR1 (0.46) | CCR1PPARGKMT2AGAATPH1 | |
| SCHEMBL15230620 | 0.88 | GAA (0.38) | CCR1PPARGKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL15230947 | 0.88 | CCR1 (0.40) | CCR1PPARGKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL15231151 | 0.87 | CCR1 (0.38) | CCR1PPARGKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL15230828 | 0.87 | GAA (0.38) | CCR1PPARGKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20727027 | 0.86 | POLB (0.44) | CCR1KMT2AMEN1GAATPH1 | |
| SCHEMBL1120082 | 0.85 | GAA (0.47) | CCR1PPARGSMN1; SMN2GAATPH1 | |
| SCHEMBL1120075 | 0.84 | CCR1 (0.41) | CCR1PPARGGAATPH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124501-A1 | Active compound combinations | BAYER CROPSCIENCE AG (DE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124501-A1 | Active compound combinations | CYP51A1, CA4, BROX | CCR1 1486/4885PPARG 402/4885KMT2A 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.